文献速递肝病消化道肿瘤与早癌

RSK2失活与AXIN1失活或β-catenin激活协同促进肝细胞癌发生

RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis.
PubMed 文献 · J Hepatol · 2023-05-16

该研究分析了1151例人肝细胞癌(HCC)中RSK2突变及20种其他驱动基因改变,并在小鼠中模拟RSK2失活在不同突变背景下的作用。结果显示RSK2失活突变特异见于人HCC,常与AXIN1失活或β-catenin激活突变共存,小鼠模型证实其协同促进肝肿瘤发生,且RSK2失活肝癌细胞对RAS/MAPK信号激活存在依赖性,可被MEK抑制剂靶向。

要点

  • RSK2失活突变特异见于人HCC,常与AXIN1失活或β-catenin激活突变共存。
  • 小鼠模型证实RSK2失活与AXIN1失活或β-catenin激活协同促进肝肿瘤发生。
  • RSK2失活肝癌细胞依赖RAS/MAPK信号激活,MEK抑制剂可靶向该通路。

核心结论

  • 本研究证明RSK2在肝脏中发挥抑癌作用,其功能丧失与AXIN1失活或β-catenin激活特异性协同促进肝细胞癌发生。
  • RSK2失活肝肿瘤中RAS/MAPK通路激活是潜在治疗靶点,可用现有抗MEK疗法靶向。

研究设计与样本

  • 分析1151例人肝细胞癌中RSK2突变及20种其他驱动基因改变。
  • 利用转基因小鼠和肝脏特异性致癌物,在多种突变背景中模拟RSK2失活,观察肝肿瘤发生并进行表型和转录组分析。
  • 在人RSK2缺陷HCC细胞系中研究RSK2恢复的功能后果。

主要发现

  • RSK2失活突变特异见于人HCC,且频繁与AXIN1失活或β-catenin激活突变共存。
  • 小鼠模型中这些共存突变协同促进肝肿瘤发生,转录组谱重现人HCC特征。
  • RSK2缺失与二乙基亚硝胺化学诱导的BRAF激活突变在肝肿瘤诱导中无协同作用。
  • 人肝癌细胞中RSK2失活赋予对RAS/MAPK信号激活的一定依赖性,可被MEK抑制剂靶向。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recurrent somatic mutations of the RPS6KA3 gene encoding for the serine/threonine kinase RSK2 were identified in hepatocellular carcinomas (HCCs), suggesting its tumour-suppressive function. Our goal was to demonstrate the tumour suppressor role of RSK2 in the liver and investigate the functional consequences of its inactivation. METHODS: We analysed a series of 1,151 human HCCs for RSK2 mutations and 20 other driver genetic alterations. We then modelled RSK2 inactivation in mice in various mutational contexts recapitulating or not those naturally found in human HCC, using transgenic mice and liver-specific carcinogens. These models were monitored for liver tumour appearance and subjected to phenotypic and transcriptomic analyses. Functional consequences of RSK2 rescue were also investigated in a human RSK2-deficient HCC cell line. RESULTS: RSK2-inactivating mutations are specific to human HCC and frequently co-occur with AXIN1-inactivating or β-catenin-activating mutations. Modelling of these co-occurrences in mice showed a cooperative effect in promoting liver tumours with transcriptomic profiles recapitulating those of human HCCs. By contrast, there was no cooperation in liver tumour induction between RSK2 loss and BRAF-activating mutations chemically induced by diethylnitrosamine. In human liver cancer cells, we also showed that RSK2 inactivation confers some dependency to the activation of RAS/MAPK signalling that can be targeted by MEK inhibitors. CONCLUSIONS: Our study demonstrates the tumour suppressor role of RSK2 and its specific synergistic effect in hepatocarcinogenesis when its loss of function is specifically combined with AXIN1 inactivation or β-catenin activation. Furthermore, we identified the RAS/MAPK pathway as a potential therapeutic target for RSK2-inactivated liver tumours. IMPACT AND IMPLICATIONS: This study demonstrated the tumour suppressor role of RSK2 in the liver and showed that its inactivation specifically synergises with AXIN1 inactivation or β-catenin activation to promote the development of HCC with similar transcriptomic profiles as found in humans. Furthermore, this study highlights that activation of the RAS/MAPK pathway is one of the key signalling pathways mediating the oncogenic effect of RSK2 inactivation that can be targeted with already available anti-MEK therapies.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Schaeffer S, Gupta B, Calatayud AL, et al. RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis. J Hepatol. 2023. PMID: 37201672. doi:10.1016/j.jhep.2023.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。